The wake-promoting agent modafi nil is approved for the treatment of excessive sleepiness associated with obstructive sleep apnea (OSA), shift work disorder (SWD), and narcolepsy. In OSA, modafi nil is recommended for use as an adjunct to standard therapies that treat the underlying airway obstruction. This article reviews the literature on modafi nil (pharmacology, pharmacokinetics, effi cacy, tolerability, and abuse potential), with emphasis on use of modafi nil in the treatment of excessive sleepiness in patients with OSA, SWD, and narcolepsy. In large-scale, double-blind, placebo-controlled studies, modafi nil improved objectively determined sleep latency, improved overall clinical condition related to severity of sleepiness, and reduced patient-reported sleepiness. Improvements in wakefulness were accompanied by improvements in behavioral alertness, functional status, and health-related quality of life. In patients with SWD, diary data showed modafi nil reduced the maximum level of sleepiness during night shift work, level of sleepiness during the commute home, and incidence of accidents or near-accidents during the commute home when compared with placebo. Modafi nil was well tolerated, without adversely affecting cardiovascular parameters or scheduled sleep. These fi ndings and those of extension studies which reported improvements were maintained suggest modafi nil has a benefi cial effect on daily life and well-being in patients with excessive sleepiness associated with OSA, SWD, or narcolepsy.
Introduction
Modafi nil, an orally administered wake-promoting agent, is indicated to improve wakefulness in adults with excessive sleepiness associated with obstructive sleep apnea (OSA), shift work disorder (SWD), and narcolepsy (PROVIGIL ® 2007) . In patients with OSA, modafi nil is recommended for use as an adjunct to standard therapies prescribed for the underlying airway obstruction (PROVIGIL ® 2007) . Modafi nil was fi rst approved in the United States in December 1998 for use in narcolepsy and subsequently in January 2004 for use in OSA and SWD. This article reviews the literature on modafi nil (pharmacology, pharmacokinetics, effi cacy, tolerability, and abuse potential), with emphasis on use of modafi nil in the treatment of excessive sleepiness in patients with OSA, SWD, and narcolepsy.
Excessive sleepiness
Excessive sleepiness is the inability to remain awake during situations when wakefulness and alertness are required or expected (Arand et al 2005; Wise 2006 ). It is a main presenting symptom of individuals seen in sleep clinics and affects a substantial proportion of the general population. In a survey conducted by the National Sleep Foundation, 37% of adults reported sleepiness severe enough to interfere with activities of daily living a few days or more each month; 16% of respondents indicated excessive sleepiness interfered with activities even more frequently (ie, a few days or more each week) (National Sleep Foundation 2002) . Objective and subjective assessments Schwartz of sleepiness in community-based samples suggest a prevalence of 24%-36% (Baldwin et al 2004; Mignot et al 2006; Singh et al 2006) . Causes of excessive sleepiness include inadequate restorative sleep due to shortened duration or fragmentation, circadian rhythm disturbance or misalignment, dysregulation of intrinsic mechanisms responsible for promoting sleep and wakefulness, and the use of sedating medications (Roth and Roehrs 1996) . Excessive sleepiness is a prominent symptom of various disorders of sleep and wakefulness (American Academy of Sleep Medicine 2001) and of other medical and psychiatric disorders.
In addition to impairing physical, cognitive, and psychosocial functioning, excessive sleepiness compromises the safety of individuals and the public at large. Sleepiness has been implicated in serious incidents in the workplace (Mitler et al 1988; Dinges 1995) , and chronic sleepiness appears to be a signifi cant independent risk factor for involvement in vehicular accidents (Gander et al 2004) . A recent crosssectional survey found road accidents due to sleepiness are not limited to commercial drivers during the night or early morning hours; near-miss accidents due to sleepiness are common among other types of drivers and appear to predict who is at risk for any type of actual accident (Powell et al 2007) . Individuals with disorders of sleep and wakefulness who have sleepiness as a prominent characteristic are among those who are at increased risk for sleep-related accidents (Lyznicki et al 1998; MacLean et al 2003; Drake et al 2004; Powell et al 2007) .
Disorders of sleep and wakefulness: obstructive sleep apnea, shift work disorder, and narcolepsy
These three sleep disorders, though differing in origin, are all distinguished by excessive sleepiness. OSA affects an estimated 2%-4% of middle-aged adults (Young et al 1993) . This chronic disorder is characterized by repeated episodes of partial or complete collapse of the upper airway during sleep. The partial or complete obstruction causes recurrent breathing diffi culties, which are associated with arousals that disrupt sleep and may also cause hypoxemia. Elevated homeostatic sleep pressure and possibly hypoxic brain injury (Gale and Hopkins 2004; Veasey et al 2004; Morrell and Twigg 2006; Polotsky et al 2006; Zhu et al 2007) contribute to excessive sleepiness and other neurobehavioral and neuropsychological impairments in these patient. Nasal continuous positive airway pressure (CPAP) is an effective intervention for OSA (Engleman et al 1994a) that works to restore patency by pneumatically splinting the airway. However, clinically signifi cant excessive sleepiness may persist for some patients who regularly use CPAP therapy (Sforza and Krieger 1992) . In patients with severe OSA and daytime sleepiness who were optimally treated with CPAP therapy (6 or more hours nightly), 8 of 36 patients (22%) subjectively reported ongoing daytime sleepiness (assessed by the Epworth Sleepiness Scale), and 12 of 23 patients (52%) had ongoing objectively determined sleepiness (assessed by the MSLT) despite optimal CPAP therapy (Weaver et al 2007) .
SWD is a circadian rhythm sleep disorder estimated to affect 32% and 26% of night shift and rotating shift workers, respectively (Drake et al 2004) . The disorder is caused by an inability to adapt internally driven processes that regulate sleep and wakefulness (ie, circadian cycles and homeostatic sleep drive) to externally imposed sleep-wake schedules. Minimal criteria for a diagnosis of SWD are a primary complaint of excessive sleepiness or insomnia and temporal association of symptoms with work that occurs during the period of habitual sleep (American Academy of Sleep Medicine 2001). Individuals with SWD have a signifi cantly greater risk for morbidity (ie, ulcers and depression) than shift workers without SWD or day workers who have identical symptoms (Drake et al 2004) .
Narcolepsy is a chronic disorder of sleep/wake regulation characterized by excessive sleepiness and symptoms of dissociated rapid eye movement sleep (ie, sleep attacks, cataplexy, hypnagogic hallucinations, and sleep paralysis). With the exception of excessive sleepiness, which occurs in 100% of patients, symptoms vary both in frequency and severity among individuals with the disorder. Narcolepsy with cataplexy is the most common variant, with an estimated prevalence of 0.02% to 0.18% (Mignot 1998) . Narcolepsy with cataplexy is associated with a defi ciency of orexin-A, also known as hypocretin-1, a hypothalamic peptide implicated in energy homeostasis and arousal (Sakurai 2007) .
Chemistry and preclinical pharmacology
Modafinil is a benzyhydrylsulfinylacetamide derivative with a molecular formula of C 15 H 15 NO 2 S. It is chemically unrelated to and pharmacologically distinguishable from the central nervous system (CNS) stimulants (eg, dextroamphetamine and methylphenidate) (Duteil et al 1990; Lin et al 1992 Lin et al , 1996 Simon et al 1994 Simon et al , 1995 Shelton et al 1995; Florence et al 2000) . The primary pharmacological activity of modafi nil is promoting wakefulness. Modafi nil has been shown to increase wakefulness in studies conducted in animal models of narcolepsy (Shelton et al 1995) and sleep-disordered breathing (Panckeri et al 1996) and in sleepdeprived human volunteers (Lagarde et al 1995; Pigeau et al 1995; Walsh et al 2004) .
Identification of the specific molecular targets that underlie the wake-promoting activity of modafi nil is ongoing. In vitro, modafi nil interacted negligibly or weakly with receptors for adenosine, dopamine, serotonin, histamine, melatonin, γ-amino butyric acid (GABA), and benzodiazepines (Mignot et al 1994; PROVIGIL ® 2007) . Modafi nil has not been shown to be an α1-adrenergic agonist, although animal studies suggest an intact α1-adrenergic system may be necessary for modafi nil-induced increases in locomotor activity (Duteil et al 1990; Hermant et al 1991; Lin et al 1992) . In contrast to amphetamine, modafi nil-induced wakefulness was not blocked by a dopamine-receptor antagonist or substantially affected by administration of an inhibitor of catecholamine synthesis (Lin et al 1992) . In vitro, modafi nil has been shown to bind weakly but selectively to the dopamine transporter (Mignot et al 1994; Nishino et al 1998; Madras et al 2006) and, to a lesser extent, the norepinephrine transporter (Madras et al 2006) . Wake-promoting concentrations of modafi nil increased extracellular levels of monoamines, including norepinephrine and dopamine, in certain rat brain regions (de Saint Hilaire et al 2001) . Mutant mice lacking the dopamine transporter gene were unresponsive to modafi nil (Wisor et al 2001) . Studies in animals suggest modafi nil increases activity in the cortex through selective actions on hypothalamic regions involved in regulating sleep and wakefulness. In a study that evaluated c-fos expression in cat brain, modafi nil discretely and differentially from amphetamine and methylphenidate activated areas of the hypothalamus implicated in maintaining normal wakefulness, including the anterior hypothalamic nucleus and surrounding areas, with labeling of few cells in the cortex (Lin et al 1996) . The authors suggested modafi nil may promote wakefulness by disinihibiting cortical neurons. Another study reported intraperitoneal administration of wake-promoting doses of modafi nil in rats induced c-fos expression in orexin neurons in the perifornical lateral hypothalamus and also increased c-fos in the tuberomammillary nucleus (TMN) of the posterior hypothalamus (Scammell et al 2000) . The TMN is the source of central histaminergic neurons, which are active during waking and mediate cortical arousal (Lin et al 1988 (Lin et al , 1990 (Lin et al , 1994 Lin 2000) . The study also reported modafi nil decreased activity in the ventrolateral preoptic nucleus (VLPO), a sleep-promoting region of the hypothalamus. The VLPO is active during sleep and provides inhibitory GABA-ergic input to neurons involved in wakefulness (Sherin et al 1996 (Sherin et al , 1998 Gallopin et al 2000) . Modafi nil also increased activity in cortical regions, including the frontal and cingulate cortex, compared with controls. In another study, intracerebroventricular injection of modafi nil increased histamine release in anesthetized rats whereas direct injection into the tuberomammillary nucleus did not, suggesting histaminergic neurons were not directly targeted (Ishizuka et al 2003) . Others have shown modafi nil may potentiate the sleep-inhibiting activity of noradrenaline in the VLPO (Gallopin et al 2004) . These fi ndings suggest modafi nil may promote wakefulness, at least in part, by indirectly activating ascending arousal systems via an inhibitory action on sleep-active neurons (Gallopin et al 2004) . This action is consistent the fi nding that modafi nil is not associated with rebound hypersomnolence (Edgar and Seidel 1997; Lin et al 2000) .
Clinical pharmacokinetics
Modafi nil is a racemic compound, with two enantiomers that are pharmacokinetically dissimilar. The R-enantiomer has a longer half-life than the S-enantiomer (10-14 h vs 3-4 h) (Wong et al 1999a; Wong et al 1999b; Robertson and Hellriegel 2003) , and the S-enantiomer has a faster rate of clearance (Wong et al 1999b) . The enantiomers have similar pharmacological properties, but because total exposure of R-modafi nil is approximately 3 times that of Smodafi nil, wake-promoting activity is likely due primarily to the R-enantiomer (Dinges et al 2006) . The R-enantiomer, also known as armodafi nil, has recently been approved to treat excessive sleepiness associated with OSA, SWD, and narcolepsy (NUVIGIL ® 2007), but is not yet commercially available. The effective elimination half-life of racemic modafi nil allows once-daily dosing.
Orally administered modafi nil is absorbed readily, with maximum plasma concentrations (C max ) occurring at 2-4 hours (Robertson and Hellriegel 2003) . Absorption (t max ) may be delayed by approximately 1 hour if modafi nil is taken with food (PROVIGIL 2007). Steady-state plasma concentrations are reached within 4 days of dosing (Robertson and Hellriegel 2003) . Modafi nil is well distributed in body tissue, with an apparent volume of distribution of 0.8 L/kg (Wong et al 1999a) . Metabolism (90%) occurs primarily through the liver, with renal elimination of metabolites (Robertson and Hellriegel 2003) . Less than 10% of the administered dose is excreted in urine as unchanged drug (Robertson and Hellriegel 2003) . Two metabolites, modafi nil acid and modafi nil sulfone, reach appreciable levels in plasma (PROVIGIL ® 2007; Robertson and Hellriegel 2003) . Modafi nil acid is the major urinary metabolite (Wong et al 1999a) . Neither metabolite appears to contribute to the wake-promoting activity of modafi nil (Robertson and Hellriegel 2003) .
The pharmacokinetics of modafi nil is not affected by gender, but oral clearance (CL/F) of modafi nil may be reduced in elderly patients (Wong et al 1999b) . Severe chronic renal failure was not shown to signifi cantly affect the pharmacokinetics of modafi nil, but plasma concentrations of an inactive metabolite increased 9-fold (PROVIGIL ® 2007). In patients with cirrhosis of the liver, oral clearance of modafi nil was decreased by ~60%, and steady state concentration was doubled compared with healthy subjects (PROVIGIL ® 2007) . Adjustments in dosing should be considered for these patient populations (Robertson and Hellriegel 2003; PROVIGIL ® 2007) .
Drug -drug interactions
Modafi nil has the potential to modulate the activities of hepatic cytochrome P450 (CYP) isoenzymes. In human liver microsomes, modafi nil reversibly inhibited CYP2C19 (Robertson et al 2000) . Because of its potential to inhibit CYP2C19, modafi nil may prolong elimination and increase circulating levels of drugs that are primarily metabolized via this enzyme (eg, diazepam, phenytoin, and propranolol). Dose reduction and toxicity monitoring may be required when drugs metabolized by CYP2C19 are coadministered with modafi nil (Robertson et al 2000; PROVIGIL ® 2007) . In individuals who are defi cient in CYP2D6, coadministration of modafi nil with substrates of CYP2D6 that have ancillary routes of elimination through CYP2C19 (eg, tricyclic antidepressants and selective serotonin reuptake inhibitors) may lead to elevated circulating levels of these drugs and require dose adjustment (Robertson et al 2000; PROVIGIL ® 2007) . Modafi nil suppressed CYP2C9 activity in cultures of human hepatocytes, suggesting a potential for drug interactions between modafi nil and enzyme substrates (eg, S-warfarin, phenytoin) (Robertson et al 2000) . Despite this in vitro fi nding, modafi nil administration for 4 weeks did not signifi cantly alter the pharmacokinetics of S-warfarin, a substrate for CYP2C9, compared with placebo in a study of healthy volunteers who were given a single dose of racemic warfarin following long-term administration of modafi nil (Robertson et al 2002a) . Because potential interactions between warfarin and other agents have also been documented, increased monitoring of prothrombin times/ International Normalized Ratio is recommended whenever modafi nil and warfarin are coadministerered (Robertson et al 2000; PROVIGIL ® 2007) .
Modafi nil also has been shown to cause a modest induction of CYP3A4, CYP2B6, and CYP1A2 in human hepatocytes (Robertson et al 2000) . Protracted daily administration of modafi nil (400 mg) decreased systemic exposure of orally administered triazolam and ethinyl estradiol, two substrates of CYP3A4, suggesting increased elimination (Robertson et al 2002b) . Dose adjustments may be necessary for patients taking these and similar medications (PROVIGIL ® 2007) . Because the effectiveness of steroidal contraceptives may be reduced when taken concurrently with modafi nil, additional or alternative methods of contraception should be used during treatment with modafi nil and for 1 month after discontinuation of modafi nil therapy (Robertson et al 2002b; PROVIGIL ® 2007) . Modafi nil is partially metabolized by CYP3A4. Coadministration of potent inducers (eg, carbamazepine, phenobarbital, rifampin) or inhibitors (eg, ketoconazole, itraconazole) of this enzyme may modify modafi nil levels in plasma (PROVIGIL ® 2007).
Clinical effi cacy and tolerability: overview of double-blind placebo-controlled studies
The efficacy and tolerability of once-daily doses Group 1998 Group , 2000 . In fi ve of the six studies, an objective measure of excessive sleepiness/ sleep latency -the Multiple Sleep Latency Test (MSLT) (Carskadon et al 1986) or the Maintenance of Wakefulness Test (MWT) (Mitler et al 1982; Doghramji et al 1997) -was chosen prospectively as a primary effi cacy measure. The MSLT and MWT measure the propensity of individuals to fall asleep or remain awake, respectively, when instructed to do so in a formalized laboratory setting. Another primary end point was the investigator-rated change in overall clinical condition for severity of sleepiness (ie, the Clinical Global Impression of Change [CGI-C] [Guy 1976] ). All six studies evaluated tolerability and safety of modafi nil administered for 4-12 weeks. The studies also evaluated subjectively determined sleepiness with the use of the Epworth Sleepiness Scale (ESS) (Johns et al 1991) or the Karolinska Sleepiness Scale (KSS) (Akerstedt et al 1982) . The 8-item ESS was used in the OSA and narcolepsy studies to determine the extent to which excessive sleepiness interfered with daily activities. The 9-item KSS was used in a SWD study (Czeisler et al 2005) because of its widespread use in the assessment of excessive sleepiness in circadian rhythm sleep disorders. Other assessments included the Psychomotor Vigilance Task (PVT) (Dinges and Powell 1985) , a test of sustained attention performance that was used to assess behavioral alertness (OSA and SWD studies); the Functional Outcomes of Sleep Questionnaire (FOSQ) (Weaver et al 1997) , a self-administered 30-item instrument that was used to determine the effect of excessive sleepiness on functional status (OSA and SWD studies); and the 36-item Short Form Health Survey (SF-36) (Ware 2007 ), a self-administered questionnaire that assessed health-related quality of life (OSA, SWD, and narcolepsy studies). Patients with SWD completed electronic diaries that contained questions about sleepiness, sleep, and caffeine use during the night shift and on the commute home.
Patients enrolled in these studies had a diagnosis of OSA, SWD, or narcolepsy and were required to meet accepted criteria for excessive sleepiness. In the OSA studies, study drug was administered in conjunction with ongoing CPAP therapy. Patients were men and women (24-76 years) with a diagnosis of OSA and evidence of residual excessive sleepiness (ie, screening/baseline ESS score of Ն10) despite CPAP use (ie, apnea-hypopnea index [AHI] of Ͻ10). In the 4-week study, 157 patients were randomly assigned to receive modafi nil (week 1, 200 mg/day; weeks 2-4, 400 mg/day) or matching placebo once daily after the morning meal (Pack et al 2001) . In the 12-week study, 309 patients were randomly assigned to receive modafi nil 200 mg, modafi nil 400 mg, or matching placebo once daily in the morning (Black and Hirshkowitz 2005 ). The starting dose was 100 mg, which was increased by 100-mg increments every 2 days until the fi nal dose was reached.
In the SWD studies, men and women (18-60 years) who were diagnosed with SWD and had excessive sleepiness during the night shift were eligible. In one of the studies, patients had to have a mean sleep latency of Յ6 minutes on a night-time MSLT (Czeisler et al 2005) . A total of 209 patients were randomly assigned to receive modafi nil 200 mg once daily or placebo, taken 1 hour before the start of the night shift. In another 12-week study, 278 patients were randomized to receive modafi nil 200 mg, modafi nil 300 mg, or placebo 30-60 minutes before each night shift (Erman et al 2007) .
In the narcolepsy studies, men and women (17-68 years) with a diagnosis of narcolepsy had sleep latencies of Յ8 minutes (for those with recurrent daytime naps or lapses into sleep that were occurring almost daily for at least 3 months, with cataplexy) or Յ5 minutes (for those with a complaint of excessive sleepiness or sudden muscle weakness, with sleep paralysis, hypnagogic hallucinations, automatic behaviors, and disrupted major sleep episode). Patients had to have 2 or more sleep-onset, rapid-eye-movement periods during administration of the MSLT. Patients (n = 285 and n = 273) were randomly assigned to receive once-daily modafi nil 200 mg/day, modafi nil 400 mg/day, or placebo for 9 weeks using a rapid dose-titration schedule (US Modafi nil in Narcolepsy Multicenter Study Group 1998) or a gradual step-up protocol (US Modafi nil in Narcolepsy Multicenter Study Group 2000) .
The 3 study populations were similar with regard to demographic characteristics (Table 1 ). There were proportionally more men than woman in the OSA studies, in keeping with the known epidemiology of the disorder. Most patients were rated as at least moderately ill with regard to sleepiness on the Clinical Global Impression of Severity. Patients were moderately to severely sleepy at baseline. In one study, mean sleep latency on the MSLT averaged approximately 2 minutes for patients with SWD (Czeisler et al 2005) . In another study, mean sleep latency 
Effi cacy outcomes OSA studies
In the 4-week study, modafinil significantly improved objectively determined wakefulness and reduced patientreported sleepiness (MSLT and ESS, respectively) compared with placebo (Table 2) (Pack et al 2001) . At week 4, 51% of patients receiving modafi nil had excessive sleepiness that normalized (ie, ESS score Ͻ10) compared with 27% of patients receiving placebo (p Ͻ 0.01). Signifi cant improvements were shown for patients receiving modafi nil compared with patients receiving placebo in 4 of 14 PVT performance variables, including the number of lapses (transformed) andthe median reaction time (Table 2) (Dinges and Weaver 2003) . Modafi nil improved functional status on the FOSQ, with signifi cant improvements in the total score and 2 of 5 subscales (ie, activity and vigilance) versus placebo after 4 weeks. Modafi nil signifi cantly improved overall clinical condition for sleepiness, with 71% of patients receiving modafi nil rated by the investigator as improved compared with 35% of patients receiving placebo (p Ͻ 0.05) (Pack et al 2001) .
In the 12-week study, modafi nil signifi cantly improved objectively determined wakefulness on the MWT, reduced sleepiness levels on the ESS, and improved the FOSQ total score and subscale scores for vigilance, general productivity, and activity but not scores for social outcome or intimacy (Table 2) (Black and Hirshkowitz 2005) . At week 12, overall clinical condition improved for 61% and 68% of patients receiving modafi nil 200 mg and 400 mg, respectively, compared with 37% of patients receiving placebo (p Ͻ 0.001) (Black and Hirshkowitz 2005) .
SWD studies
In one 12-week study, modafinil 200 mg significantly improved nighttime sleep latency on the MSLT, reduced levels of sleepiness on the KSS, and reduced the frequency of performance lapses on the PVT (Table 3) (Czeisler et al 2005) . A greater proportion of patients receiving modafi nil were rated as improved at the fi nal visit on the CGI-C than patients receiving placebo (74% vs 36%) (p Ͻ 0.001). As reported in patient diaries, modafi nil 200 mg reduced the maximum level of sleepiness during night shift work compared with placebo (mean change from baseline, -1.9 [1.4] vs -0.9 [1.0]) (p Ͻ 0.001) and the level of sleepiness during the commute home (-1.1 [1.5] vs -0.6 [1.2]) (p = 0.01). Fewer patients receiving modafi nil than placebo reported having accidents or near accidents on the commute home (29% vs 54%) (p Ͻ 0.001). Modafi nil was not associated with statistically signifi cant effects on unintentional or intentional sleep episodes, caffeine intake, or mistakes, accidents, or near accidents during night shifts. During days following nights when the night shifts were not worked, no differences were reported in caffeine use or sleep effi ciency between modafi nil and placebo.
In another 12-week study, modafi nil improved aspects of daily functioning and health-related quality of life the day after shifts compared with placebo (Table 3) (Erman et al 2007) . The FOSQ total score was significantly improved with modafinil 300 mg, as were vigilance, activity, and productivity subscale scores. No signifi cant improvement was shown with modafi nil 300 mg in social outcome or intimacy. Modafinil 200 mg significantly improved the activity subscale score compared with placebo. Signifi cant improvements were shown for the SF-36 mental component score and the vitality and role-emotional domain scores.
Narcolepsy studies
In both studies, modafi nil 200 and 400 mg signifi cantly improved objectively determined sleep latency (MSLT and MWT) and subjectively assessed sleepiness levels (ESS) compared with placebo (Table 4 ) (US Modafi nil in Narcolepsy Multicenter Study Group 1998 Group , 2000 . Modafi nil signifi cantly improved health-related quality of life on the SF-36 compared with placebo, with greater vitality, fewer constraints on daily activities due to physical or emotional limitations, and less interference with social activities due to health (Table 4) (Beusterien et al 1999) . No signifi cant treatment effect was shown for physical functioning, bodily pain, general health, or mental health.
Tolerability and safety outcomes
In these double-blind placebo-controlled studies, 1501 patients received 200, 300, or 400 mg of modafi nil (n = 934) or placebo (n = 567) for up to 12 weeks (Roth et al 2007) . Safety was assessed in these studies by monitoring adverse events, vital signs (ie, resting systolic and resting diastolic blood pressures, heart rate, and body weight), electrocardiogram (ECG) intervals, clinical laboratory parameters, and polysomnographic parameters collected during the day (OSA and narcolepsy) or night (SWD). Across the studies, adverse event profi les were similar, with headache (34%), nausea (11%), infection (10%), nervousness (7%), rhinitis (7%), diarrhea (6%), back pain (6%), anxiety (5%), dizziness, (5%), dyspepsia (5%), and insomnia (5%) the most common treatment-emergent adverse events ( Roth et al 2007) . Headache was considered to be dose related (Roth et al 2007) . Adverse events that occurred more frequently with modafi nil than placebo were headache, nausea, nervousness, anxiety, insomnia, anorexia, dry mouth, hypertension, and pharyngitis (p Ͻ 0.05 vs placebo) (Roth et al 2007) . Most adverse events (nearly 90%) occurred during the fi rst month and were considered by the investigator to be mild to moderate in nature (PROVIGIL ® 2007; Roth et al 2007) . For the combined modafi nil group, the cumulative incidence of headache was 20% at week 1 (vs 9% for placebo), 29% at month 1 (vs 18% for placebo), and 34% at month 3 (vs 23% for placebo) (Roth et al 2007) . Across the studies, 8% of patients receiving modafi nil discontinued because of an adverse event compared with 3% of patients receiving placebo (PROVIGIL ® 2007; Roth et al 2007) . The most frequently occurring adverse event associated with discontinuation was headache (2%) (Roth et al 2007) .
Although a small but statistically signifi cant difference in the mean change from baseline in sitting systolic blood pressure was observed between modafi nil and placebo in the 4-week OSA study (Pack et al 2001) , no signifi cant changes from baseline to fi nal visit in mean systolic blood pressure, diastolic blood pressure, or heart rate were shown between modafi nil and placebo for the combined OSA studies or the combined SWD studies (Roth et al 2007) . In the combined narcolepsy studies, a signifi cant between-group difference in heart rate and blood pressure was demonstrated; the difference was attributable to a greater change from baseline for placebo than modafi nil (Roth et al 2007 Across the studies, no signifi cant changes from baseline were shown in mean body weight. Clinically signifi cant decreases in weight (ie, Ն7% from baseline) were reported for 3% of patients receiving modafi nil (Roth et al 2007) . No treatment-emergent pattern of electrocardiographic abnormalities was found following modafi nil administration (PROVIGIL ® 2007; Roth et al 2007) . Mean plasma levels of gamma glutamyltransferase and alkaline phosphatase were higher following administration of modafi nil but not placebo (PROVIGIL ® 2007; Roth et al 2007) . Clinically signifi cant abnormalities in laboratory parameters were rare and reported in Ͻ1% of patients receiving modafi nil or placebo (Roth et al 2007) .
In these studies, modafi nil did not adversely affect scheduled sleep. No clinically meaningful or statistically signifi cant differences shown between groups in polysomnographically determined sleep parameters, including sleep effi ciency, sleep duration, and stages of sleep (US Modafi nil in Narcolepsy Multicenter Study Group 1998 Group , 2000 Pack et al 2001; Hirshkowitz 2005, Czeisler et al 2005) . In the 4-week OSA study, mean arousal index (ie, the number of arousals per hour of sleep) was slightly greater for patients receiving modafi nil than patients receiving placebo (14.3 vs 11.8) (p = 0.018) (Pack et al 2001) . In a 9-week narcolepsy study, sleep effi ciency was slightly better for the modafi nil 200-mg group than the placebo group (US Modafi nil in Narcolepsy Multicenter Study Group 2000). Modafi nil was not associated with symptoms of withdrawal (eg, fatigue, agitation, vivid dreams, hypersomnia, or increased appetite) when its use was discontinued for 2 weeks following 9 weeks of administration in patients with narcolepsy (US Modafi nil in Narcolepsy Multicenter Study Group 2000).
Additional safety data
More than 3500 patients have been evaluated for safety in clinical studies of modafi nil for treatment of excessive sleepiness associated with OSA, SWD, and narcolepsy (Schwartz 2005; PROVIGIL ® 2007) . The type and incidence of adverse events have been consistent with those reported in the placebo-controlled trials. Serious rash requiring hospitalization and treatment discontinuation have been reported in association with modafi nil use (FDA 2007; PROVIGIL ® 2007) . In worldwide postmarketing experience, rare cases (exceeding the background incidence rate in the general population of 1-2 cases per million-person years) of serious or life-threatening rash, including Stevens-Johnson Syndrome, have been reported in adults and children. No factors are known that may be used to predict either rash occurrence or severity. It is recommended that modafi nil be discontinued at the fi rst sign of rash unless the rash is clearly not related to the drug.
Extension studies
An open-label extension of the 4-week OSA study reported improvements in wakefulness and sleep-related functional status were maintained for 12 additional weeks in patients receiving CPAP therapy (Schwartz et al 2003c) . In a long-term open-label extension conducted in patients who participated in the 12-week OSA study, improvements in subjectively determined wakefulness, functional status, and health-related quality of life were maintained with modafi nil for 12 months (Schwartz 2005; Hirshkowitz and Black 2007) . The extension study did not evaluate objectively determined sleep latency. Modafi nil continued to be well tolerated, with infection (11.3%), headache (9.4%), and nervousness (9.0%) being the most common adverse events reported (Hirshkowitz and Black 2007) . Although no substantial alterations were reported in the mean change from baseline in blood pressure and heart rate, a clinically signifi cant elevation in blood pressure was reported for 6 patients (2%) (at a single evaluation for 5 patients and at 2 consecutive evaluations for 1 patient). Five of these patients had a history of hypertension.
Patients from the narcolepsy studies participated in open-label extensions in which they received modafi nil 200 mg to 400 mg once daily (Mitler et al 2000; Schwartz 2005) . Improvements in wakefulness with modafi nil were maintained through 136 weeks of open-label administration. Modafi nil was well tolerated, with a low likelihood for the development of tolerance.
Additional clinical studies
In addition to the large-scale placebo-controlled studies and long-term extension studies, other clinical studies and case reports have reported improvements in wakefulness with modafi nil in patients with OSA (Kingshott et al 2001; Schwartz et al 2003c) and narcolepsy (Billiard et al 1994; Besset et al 1996; Broughton et al 1997; Moldofsky et al 2000; Thorpy et al 2003; Schwartz et al 2003a Schwartz et al , b, 2004 Schwartz et al , 2005 . In a double-blind crossover study of 30 patients with OSA who were receiving CPAP therapy, modafi nil had no effect on sleepiness as assessed on the MSLT or the ESS but signifi cantly improved wakefulness on the MWT (Kingshott et al 2000) . In patients with narcolepsy, a 24-week study which included three 2-week double-blind crossover periods, a 16-week open-label period, and a 2-week placebocontrolled discontinuation period reported improvements in objectively determined wakefulness and subjective sleepiness that were comparable to improvements shown in the 9-week double-blind narcolepsy studies (Broughton et al 1997; Moldofsky et al 2000) .
Dosing
The recommended dose of modafi nil is 200 mg, to be taken once daily in the morning for patients with OSA or narcolepsy, or approximately 1 hour before the start of the work shift for patients with SWD (PROVIGIL ® 2007). Once daily doses of up to 400 mg have been well tolerated in randomized placebo-controlled studies. However, in the 9-week studies of narcolepsy patients, the 400-mg dose did not provide any benefi t beyond that shown for the 200-mg dose (US Modafi nil in Narcolepsy Multicenter Study Group 1998 Group , 2000 . While no clear dose response was observed in these placebo-controlled studies, a double-blind crossover study (n = 32) subsequently showed modafi nil 400 mg, taken once daily or as a split dose in the morning and at midday, was signifi cantly better at promoting wakefulness throughout the entire day than modafi nil 200 mg taken once-daily in the morning (both p Ͻ 0.05) (Schwartz et al 2003b) . The different fi ndings between the placebo-controlled studies and the crossover and parallel studies likely refl ect, at least in part, methodological differences in the execution and timing of sleep latency (MWT) testing protocols.
Dose-response effects were confi rmed and expanded in a subsequent analysis of 2 double-blind parallel group studies conducted in patients with narcolepsy (n = 56) . Modafi nil (200 mg once daily, 400 mg once daily, 400 mg split-dose, and 600 mg split-dose) signifi cantly improved patients' ability to sustain wakefulness compared with baseline in a dose-dependent manner (p Ͻ 0.05), with split-dose regimens producing signifi cantly greater improvement in MWT sleep latency than once-daily regimens in the afternoon and evening. These studies utilized an extended-day MWT, assessing the ability to remain awake at 2-hour intervals from 9 am to 9 pm. Another study showed modafi nil 600 mg taken as split dose was signifi cantly more effective than modafi nil 400 mg once daily in improving late-day MWT sleep latency in patients with narcolepsy (n = 24) . Others have reported modafi nil taken as a split dose in the morning and at midday (300-500 mg) did not adversely affect the quantity or quality of nighttime sleep in placebo-controlled, crossover studies (Billiard et al 1994; Broughton et al 1997; Moldofsky et al 2000) . Dose escalation or split-dose regimens may be important for patients who have satisfactory responses to modafi nil in the morning and afternoon but experience excessive sleepiness in the late afternoon or evening.
Abuse potential
Modafi nil is listed in Schedule IV of the Controlled Substances Act (PROVIGIL ® 2007) because its potential for abuse is relatively low and may lead to limited physical or psychological dependence. In one preclinical study, the reinforcing and stimulant-discriminative effects of modafi nil were approximately 250 times less potent than amphetamine (Gold and Balster 1996) . Another preclinical study reported modafi nil did not produce reinforcing or rewarding effects in stimulant-naïve animals (Deroche-Gamonet et al 2002) . In clinical studies conducted in healthy volunteers with no current or past history of substance abuse (Warot et al 1993) and in volunteers with histories of illicit drug use (Jasinski 2000; Rush et al 2002a, b) , modafi nil could be distinguished from CNS stimulants on the basis of subjective effects (eg, elation or euphoria). Postmarketing surveillance (over 4 years) has found no generalized misuse of modafi nil, suggesting its potential for abuse on a large scale is limited (Myrick et al 2004) .
Therapeutic considerations and clinical implications
Identifi cation of the underlying causes of excessive sleepiness, including any sleep disorders, is critical to its successful management. Persistent or severe sleepiness that interferes with daily function and poses undue health burdens or safety risks may require pharmacologic therapy. Modafi nil may be prescribed for patients who have been evaluated for excessive sleepiness and have a diagnosis of OSA, SWD, or narcolepsy.
Across large-scale, double-blind studies, placebocontrolled studies, modafi nil signifi cantly improved sleep latency on the MSLT and ability to maintain wakefulness on the MWT, improved overall clinical condition for sleepiness severity, and reduced patient-reported sleepiness on the ESS and KSS. Improvements in wakefulness were accompanied by improvements in behavioral alertness, functional status, and health-related quality of life. Modafi nil was well tolerated in the double-blind placebo-controlled studies and long-term studies. Noteworthy was the fi nding that modafi nil did not elevate mean blood pressure or heart rate relative to placebo in populations at risk for cardiovascular morbidity (ie, patients with OSA [Nieto et al 2000; Peppard et al 2000; ] and night shift workers [Kawachi et al 1995; Tenkanen et al 1997] ) (Roth et al 2007) .
The MSLT and MWT were primary measures of effi cacy in the double-blind placebo-controlled studies. As objective measures of sleep latency, the MSLT and the MWT are used in research and clinical settings. Of the two, the MSLT is used more widely and is considered to be a standard test for sleepiness by most sleep medicine specialists (Wise 2006) . The strengths and weaknesses of the MSLT and MWT have been described in a recent review that evaluated their clinical usefulness (Arand et al 2005) . While these tests do not appear to adequately discriminate between patients with sleep disorders and control subjects due in part to fl oor (MSLT) and ceiling (MWT) effects and to large standard deviations (Arand et al 2005) , they effectively monitor changes caused by interventions that alter sleepiness or alertness (Arand et al 2005) . The MSLT in particular appears to be sensitive to changes in sleepiness across the 24-hour day and following long-term sleep debt or extension (Seidel et al 1984; Roehrs et al 1996) . In addition, sleep latencies have been shown to refl ect circadian changes in studies that simulated night shift conditions (Arand et al 2005) , suggesting responses occur as expected when sleep cycles are reversed (eg, for night shift workers). Whether establishing a diagnosis or evaluating a response to treatment, sleep latency test fi ndings should be interpreted within the context of other available medical information and testing (Arand et al 2005) .
OSA is a common cause of excessive sleepiness, and residual sleepiness occurs in some patients who are otherwise well treated for the underlying airway obstruction (Weaver et al 2007) . While modafi nil reduces residual sleepiness in these patients, it does not treat the cause of OSA. It is therefore critical that patients adhere to interventions that directly address OSA-related pathology, such as CPAP therapy (Hirshkowitz and Black 2007 ). Weaver and colleagues established a relationship between hours of CPAP use during the night and achieving normal levels of daytime sleepiness and functioning; for example, thresholds above which further improvements were less likely for ESS was 4 hours, MSLT was 6 hours, and FOSQ was 7.5 hours (Weaver et al 2007) . Despite concerns to the contrary (Pollak 2003) , modafi nil does not appear to adversely affect CPAP use. While a statistically signifi cant 12-minute reduction in nightly CPAP use was shown for patients receiving modafi nil compared with patients receiving placebo in a 7-week, placebo-controlled crossover study of 30 patients (Kingshott et al 2000) , modafi nil did not signifi cantly alter CPAP use in the large-scale, 4-week and 12-week doubleblind studies (Pack et al 2001; Black and Hirshkowitz 2005) . In a 12-month follow-up to the 12-week study, mean nightly CPAP use declined by 34 minutes (p Ͻ 0.0001 for the change from baseline) to a fi nal visit duration of 5.4 hours (Hirshkowitz and Black 2007) . This duration is within the range of previously reported values for long-term CPAP use (4.3-6.5 hours) (Engleman et al 1994b; Reeves-Hoche et al 1994; Krieger et al 1996; Pieters et al 1996; Collard et al 1997) . As a precaution, CPAP use should be encouraged and periodically assessed (Black and Hirshkowitz 2007; PROVIGIL ® 2007) . Diffi culties with CPAP use, such as inadequate CPAP pressure and microarousals and sleep disruption caused by wearing the CPAP apparatus, should be addressed (Hirshkowitz and Black 2007) .
Given the large number of individuals who work night shifts on a rotating or permanent basis or work early morning shifts (Beers 2000) , recognition and diagnosis of SWD remains a pressing clinical issue. The adverse consequences of shift work may be limited to those individuals who show a differential vulnerability to the effects of sleep loss (Drake et al 2004; Van Dongen et al 2004) . Such individuals may be predisposed to developing SWD. Patients with SWD appear to be as sleepy during the night as patients with narcolepsy are during the day. Mean improvements with modafi nil in MSLT sleep latency in patients with SWD were similar in magnitude to improvements reported for patients with narcolepsy who were treated with modafi nil (US Modafi nil in Narcolepsy Multicenter Study Group 1998 Group , 2000 and to improvement reported in a meta-analysis of studies conducted in patients with OSA who were treated with CPAP therapy (0.74 min more than placebo) (Patel et al 2003) . Although sleep latency was improved by nearly 2 minutes, it averaged less than 5 minutes during the night, below what is considered to be normal during the daytime (Czeisler et al 2005) . Similarly, mean sleep latencies have been reported to improve but not to normalize completely in patients with narcolepsy, either with modafi nil or CNS stimulants (US Modafi nil in Narcolepsy Multicenter Study Group 1998; Mitler 1991) . Despite the lack of normalization, improvements across objective and subjective measures, including those for sleepiness, overall clinical condition, and behavioral alertness (Czeisler et al 2005) , together with improvements in functional status and health-related quality of life (Erman et al 2007) and diary data that showed proportionally fewer patients reporting accidents or near accidents (Czeisler et al 2005) , suggest modafi nil administration is associated with clinically meaningful improvement in these patients. Because modafi nil may not completely eliminate excessive sleepiness in all patients, individuals should be advised to avoid activities that are potentially dangerous (eg, driving or operating machinery) or require appropriate levels of wakefulness until and unless modafi nil affords suffi cient wakefulness (PROVIGIL ® 2007). Modafi nil is an established fi rst-line therapy for excessive sleepiness in patients with narcolepsy Billiard et al 2006) . An evaluation of adverse events and the potential for abuse must be made on an individual basis when prescribing modafi nil or other therapies for excessive sleepiness.
Conclusions
Multiple clinical studies indicate modafi nil is an effi cacious and well-tolerated therapy in the clinical management of excessive sleepiness in patients with OSA with ongoing sleepiness despite CPAP therapy, SWD, and narcolepsy. Long-term studies suggest continued effi cacy, with a low likelihood of tolerance and no adverse effects on scheduled sleep. Abuse liability studies show a limited potential for abuse.
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